Roche comes up empty in effort to block Amgen’s Avastin biosimilar

Roche (OTCQX:RHHBY) has come up empty in its appeal of a court ruling allowing Amgen (AMGN +0.9%) to sell Mvasi (bevacizumab-awwb), an Avastin biosimilar, in the U.S.

It also struck out in its attempt to block the latter’s Kanjinti (trastuzumab-anns), a Herceptin biosimilar.

https://seekingalpha.com/news/3588722-roche-comes-up-empty-in-effort-to-block-amgens-avastin-biosimilar